Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Y90-labeled microspheres and mitomycin C for chemorefractory breast cancer liver metastases
2012-000454-58Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Mar 2012
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of yttrium-90 microspheres and mitomycin c in breast cancer, sponsored by UZ Leuven. Primary endpoint: Systemic toxicity (CTC 4.0). Started Mar 2012; status: completed.
02
Drugs
yttrium-90 microspheresmitomycin c
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-000454-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000454-58.